Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice

Autoři: Pablo Plaza-Ramos aff001;  Enrique Borque aff001;  Alfredo García-Layana aff002
Působiště autorů: Ophthalmology Department, Complejo Hospitalario de Navarra, Pamplona, Spain aff001;  Ophthalmology Department, Clínica Universitaria de Navarra, Pamplona, Spain aff002
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0223793



To evaluate the efficacy and safety of ranibizumab and aflibercept in the treatment of diabetic macular edema in a real world study, and to compare the two treatments with each other.


Retrospective observational study of 213 eyes from 141 patients with diabetic macular edema was completed between June 2014 and June 2016. 122 were treated with ranibizumab intravitreal injection and 91 with aflibercept intravitreal injection, with a loading phase of 3 injections and a Pro Re Nata protocol. The drug was selected by the physician and fluorescein angiography was performed by physician`s criteria. Re-treatment was performed when a decline in BCVA, an increase of central macular thickness or an increase or persistence of intraretinal fluid in OCT was observed. The primary outcome was the mean change in best corrected visual acuity at 1 year, while central macular thickness, central macular volume, the number of injections and visits were evaluated as secondary outcomes. The correlation between BCVA at 4th month visit and BCVA at 12th month visit was also evaluated.


The mean baseline best corrected visual acuity for the eyes treated with ranibizumab was 0.55 (+/- 0.35) logMAR, and with aflibercept it was 0.48 (+/- 0.29) (P = 0.109). Best corrected visual acuity improved in both groups, and at the end of the follow-up was 0.40 (+/- 0.35) in the ranibizumab group and 0.40 (+/- 0.29) in the aflibercept group (P = 0.864). Best corrected visual acuity at 4th month visit is correlated at a high value (R = 0.789) with the one at the end of the study. No differences were found in central macular thickness, central macular volume and glycosylated hemoglobin when adjusting with baseline values. The overall number of injections was 5.77 (+/- 2.01), being 5.56 (+/- 2.0) in the ranibizumab group and 6.07 (+/- 1.99) in the aflibercept group (P = 0.069). The main outcome determining final best corrected visual acuity was the baseline best corrected visual acuity (P<0.001).


There are no differences in efficacy between ranibizumab and aflibercept in diabetic macular edema treatment in this real world study.

Klíčová slova:

Cataract surgery – Eyes – Lasers – Visual acuity – Vascular permeability – Pars plana vitrectomy


1. Patrao NV, Antao S, Egan C, Omar A, Hamilton R, Hykin PG, et al. Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting. Am J Ophthalmol. 2016;172:51–7. doi: 10.1016/j.ajo.2016.09.002 27637784

2. Campos Polo R, Rubio Sánchez C, García Guisado DM, Díaz Luque MJ. Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. Clin Ophthalmol. 2018;12:99–104. doi: 10.2147/OPTH.S154421 29386883

3. Bresnick GH. Diabetic macular edema. A review. Ophthalmology. 1986;93(7):989–97. doi: 10.1016/s0161-6420(86)33650-9 3531959

4. Fouda SM, Bahgat AM. Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clin Ophthalmol. 2017;11:567–71. doi: 10.2147/OPTH.S131381 28356711

5. Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data. Int J Retina Vitreous. 2016;2:16. doi: 10.1186/s40942-016-0041-z 27847634

6. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25. doi: 10.1016/j.ophtha.2011.01.031 21459215

7. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039 22330964

8. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045–53. doi: 10.1016/j.ophtha.2013.11.041 24491642

9. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22. doi: 10.1016/j.ophtha.2013.02.034 23706949

10. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015;122(10):2044–52. doi: 10.1016/j.ophtha.2015.06.017 26198808

11. Hashmonay R, Parikh S. Re: Korobelnik et al.: Intravitreal aflibercept for diabetic macular edema (Ophthalmology 2014;121:2247–54). Ophthalmology. 2015;122(6):e37–38. doi: 10.1016/j.ophtha.2014.09.041 26008915

12. Chang AA, Hong T, Ewe SY, Bahrami B, Broadhead GK. The role of aflibercept in the management of diabetic macular edema. Drug Des Devel Ther. 2015;9:4389–96. doi: 10.2147/DDDT.S62778 26273198

13. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203. doi: 10.1056/NEJMoa1414264 25692915

14. Maggio E, Sartore M, Attanasio M, Maraone G, Guerriero M, Polito A, et al. Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting. Am J Ophthalmol. 2018.

15. Haq S, Ansari WH, Han MM, Conti TF, Conti FF, Silva FQ, et al. Characterization of the Systemic Findings of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmic Surg Lasers Imaging Retina. 2019;50(1):16–24. doi: 10.3928/23258160-20181212-03 30640391

16. Venkatesh P. Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351–1359). Ophthalmology. 2017;124(4):e37–8.

17. Shalchi Z, Okada M, Bruynseels A, Palethorpe D, Yusuf A, Hussain R, et al. Effect of glycosylated hemoglobin on response to ranibizumab therapy in diabetic macular edema: real-world outcomes in 312 patients. Can J Ophthalmol. 2018;53(4):415–9. doi: 10.1016/j.jcjo.2017.10.008 30119798

18. Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018;136(3):257–69. doi: 10.1001/jamaophthalmol.2017.6565 29392288

19. Pearce I, Banerjee S, Burton BJL, Chakravarthy U, Downey L, Gale RP, et al. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Ophthalmology. 2015;122(9):1811–9. doi: 10.1016/j.ophtha.2015.05.038 26150052

20. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e35. doi: 10.1016/j.ophtha.2010.02.031 20427088

21. Granström T, Forsman H, Lindholm Olinder A, Gkretsis D, Eriksson JW, Granstam E, et al. Patient-reported outcomes and visual acuity after 12months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting. Diabetes Res Clin Pract. 2016;121:157–65. doi: 10.1016/j.diabres.2016.09.015 27718374

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden